Cost impact of prospective HLA-B*5701-screening prior to abacavir/lamivudine fixed dose combination use in Germany

European Journal of Medical Research

M Stoll¹  R Walli⁸  M Baudewig²  R Welte²  H Jaeger³  MC Mueller⁷  D Gorriahn⁴  W Becker⁶  JR Bogner⁷  M Blankenburg⁹  E Wolf⁵ 

[1] Hannover Medical School, Dept. Clinical Immunology and Rheumatology, Hannover, Germany;GlaxoSmithKline, Munich, Germany;MVZ Karlsplatz - HIV Research and Clinical Care Centre Munich, Munich, Germany;Private Practice Dr. Gorriahn, Munich, Germany;MUC Research, Munich, Germany;Private Practice Dr. Becker/Dr. Pauli, Munich, Germany;Department of Infectious Diseases, Medizinische Poliklinik, University Hospital of Munich, Munich, Downtown Campus; Germany;ViiV Healthcare, Munich, Germany;IBE, Ludwig-Maximilian University, Munich, Germany

关键词: abacavir;    pharmacogenomics;    HLA-B*5701;   

Others  :  1093257
DOI  :  10.1186/2047-783X-15-4-145

 received in 2009-07-19, accepted in 2010-03-04,  发布年份 2010

【 摘 要 】

Objective

Avoiding abacavir in HIV-infected patients tested positive for HLA-B*5701 reduces the risk of abacavir hypersensitivity reaction (ABC-HSR). Our aim was to assess the costs of clinically suspected HSR and to estimate potential cost savings of implementing prospective HLA-B*5701-screening for HIV-infected patients initiating abacavir/lamivudine fixed-dose combination (ABC/3TC FDC) compared to initiating respective treatment without screening.

Methods

Employing a decision tree model the expected HSR-related costs of screening vs. no screening were estimated from the societal and healthcare payer perspective (reference year 2007). A retrospective standardized assessment of all clinically suspected ABC-HSR cases without screening at 5 German HIV-centres was performed to measure resource consumption. In- and outpatient care, discarded ABC/3TC FDC and concomitant medication were considered. Direct resource utilization was valued using German fees (EBM, G-DRGs). Indirect costs were measured with the human capital approach. Estimates for the HLA-B*5701-prevalence, HSR-incidence, and hospitalization rate were based on clinical trials and cohorts and it was assumed that screening reduces the incidence of clinically suspected ABC-HSR from 10% to 0.5%.

Results

Thirty-two ABC-HSR cases were identified from 1998 to 2007. Mean direct and total costs per clinically suspected HSR case were € 1,362 and € 2,235, respectively. Hospital costs contributed 63.3% to direct costs. Potential cost savings when implementing genetic screening were estimated at € 44 and € 127 per screened patient, from a healthcare payer or societal perspective.

Conclusion

HLA-B*5701 screening prior to ABC/3TC FDC initiation prevents significant HSR-related costs per screened patient and is likely to lead to overall net savings.

【 授权许可】

   
2010 I. Holzapfel Publishers

【 图 表 】

Figure 1.

Figure 2.

【 参考文献 】

• [1]Lee W, Lockhart AC, Kim RB, Rothenberg ML: Cancer pharmacogenomics: powerful tools in cancer chemotherapy and drug development. Oncologist 2005, 10:104-111.
• [2]Eichelbaum M, Ingelman-Sundberg M, Evans WE: Pharmacogenomics and individualized drug therapy. Annu Rev Med 2006, 57:119-137.
• [3]Veenstra DL, Higashi MK, Phillips KA: Assessing the cost-effectiveness of pharmacogenomics. AAPS Pharm-Sci 2000, 2:E29.
• [4]Flowers CR, Veenstra D: The role of cost-effectiveness analysis in the era of pharmacogenomics. Pharmacoeconomics 2004, 22:481-493.
• [5]Owen A, Pirmohamed M, Khoo SH, Back DJ: Pharmacogenetics of HIV therapy. Pharmacogenet Genomics 2006, 16:693-703.
• [6]Ritchie MD, Haas DW, Motsinger AA, et al.: Drug transporter and metabolizing enzyme gene variants and non-nucleoside reverse-transcriptase inhibitor hepatotoxicity. Clin Infect Dis 2006, 43:779-782.
• [7]Rotger M, Colombo S, Furrer H, et al.: Influence of CYP2B6 polymorphism on plasma and intracellular concentrations and toxicity of efavirenz and nevirapine in HIV-infected patients. Pharmacogenet Genomics 2005, 15:1-5.
• [8]Saitoh A, Sarles E, Capparelli E, et al.: CYP2B6 genetic variants are associated with nevirapine pharmacokinetics and clinical response in HIV-1-infected children. AIDS 2007, 21:2191-2199.
• [9]Hetherington S, Hughes AR, Mosteller M, et al.: Genetic variations in HLA-B region and hypersensitivity reactions to abacavir. Lancet 2002, 359:1121-1122.
• [10]Mallal S, Nolan D, Witt C, et al.: Association between presence of HLA-B*5701, HLA-DR7, and HLA-DQ3 and hypersensitivity to HIV-1 reverse-transcriptase inhibitor abacavir. Lancet 2002, 359:727-732.
• [11]Martin AM, Nolan D, James I, et al.: Predisposition to nevirapine hypersensitivity associated with HLADR-B1*0101 and abrogated by low CD4 T-cell counts. AIDS 2005, 19:97-99.
• [12]Saag M, Balu R, Brachman P, et al.: High sensitivity of HLA-B*5701 in whites and blacks in immunologically-confirmed cases of abacavir hypersensitivity. In 4th International AIDS Society Conference on HIV Pathogenesis, Treatment and Prevention. Sidney, Australia. Abstract WEAB305; 2007.
• [13]Hetherington S, McGuirk S, Powell G, et al.: Hypersensitivity reactions during therapy with the nucleoside reverse transcriptase inhibitor abacavir. Clin Ther 2001, 23:1603-1614.
• [14]Mallal S, Phillips E, Carosi G, et al.: HLA-B*5701 screening for hypersensitivity to abacavir. N Engl J Med 2008, 358:568-579.
• [15]Moyle GJ, DeJesus E, Cahn P, et al.: Abacavir once or twice daily combined with once-daily lamivudine and efavirenz for the treatment of antiretroviral-naive HIV-infected adults: results of the Ziagen Once Daily in Antiretroviral Combination Study. J Acquir Immune Defic Syndr 2005, 38:417-425.
• [16]Symonds W, Cutrell A, Edwards M, et al.: Risk factor analysis of hypersensitivity reactions to abacavir. Clin Ther 2002, 24:565-573.
• [17]Guidelines for the Use of Antiretroviral Agents in HIV-1-Infected Adults and Adolescents: DHHS Panel on Antiretroviral Guidelines for Adults and Adolescents [cited on 19 February 2009]. 2008. Available from http://aidsinfo.nih.gov/contentfiles/AdultandAdolescentGL.pdf webcite
• [18]EACS Guidelines for the Clinical Management and Treatment of HIV-infected Adults in Europe: Version 4. EACS [cited on 19 February 2009]. 2008. Available from http://www.eacs.eu/Guidelines_Livret/index.htm webcite
• [19]Leitlinien für Diagnostik und Therapie der HIV-Infektion: DAIG (Deutsche AIDS-Gesellschaft) & ÖAG (Öster-reichische AIDS-Gesellschaft) [cited on 13 June 2008]. Available from http://www.daignet.de/site-content/hiv-therapie/leitlinien-1 webcite
• [20]BfArM Risikoinformationen Abacavir: BfArM (Bundesinstitut für Arzneimittel und Medizinprodukte) [cited on 13 June 2008]. Available from http://www.bfarm.de/cln_029/nn_421158/DE/Pharmakovigilanz/risikoinfo/abacavir.html__nnn=true webcite
• [21]Hughes DA, Vilar FJ, Ward CC, Alfirevic A, Park BK, Pirmohamed M: Cost-effectiveness analysis of HLA B*5701 genotyping in preventing abacavir hypersensitivity. Pharmacogenetics 2004, 14:335-342.
• [22]Schackman BR, Scott CA, Walensky RP, Losina E, Freed-berg KA, Sax PE: The cost-effectiveness of HLA-B*5701 genetic screening to guide initial antiretroviral therapy for HIV. AIDS 2008, 22:2025-2033.
• [23]Welte R, Koenig H, Jager J, Leidl R: Assessment of indirect costs of injecting drug use: which methods should be employed? In Hepatitis C and injecting drug use: impact, costs and policy options. European Monitoring Centre for Drugs and Drug Addicition Monographs 7. Edited by Jager J, Limburg W, Kretzmar M, Poostma M, Wiessing L. Luxembourg: Office for Official Publications of the European Communities; 2004:249-267.
• [24]Clay PG: The abacavir hypersensitivity reaction: a review. Clin Ther 2002, 24:1502-1514.
• [25]Cutrell AG, Hernandez JE, Fleming JW, et al.: Updated clinical risk factor analysis of suspected hypersensitivity reactions to abacavir. Ann Pharmacother 2004, 38:2171-2172.
• [26]Kivexa Product Information Kivexa-H-C-581-II-18 EMEA [cited on 29 February 2008]Available from http://www.emea.europa.eu/humandocs/Humans/EPA R/kivexa/kivexa.htm webcite
• [27]Esser S, van Lunzen J, Baudewig M, et al.: Phenotype Frequency of HLA-B*5701 in HIV-Infected Patients in Germany. In 9 Kongress für Infektiologie und Tropenmedizin. Innsbruck, Switzerland. Abstract P219; 2008.
• [28]Zucman D, Truchis P, Majerholc C, Stegman S, Caillat-Zucman S: Prospective screening for human leukocyte antigen-B*5701 avoids abacavir hypersensitivity reaction in the ethnically mixed French HIV population. J Acquir Immune Defic Syndr 2007, 45:1-3.
• [29]Rauch A, Nolan D, Martin A, McKinnon E, Almeida C, Mallal S: Prospective genetic screening decreases the incidence of abacavir hypersensitivity reactions in the Western Australian HIV cohort study. Clin Infect Dis 2006, 43:99-102.
• [30]Zahlenbericht der privaten Krankenversicherung 2006/2007 Verband der privaten Krankenversicherung e.V. [cited on 11 December 2007]Available from http://www.pkv.de/zahlen/zahlenbericht_2006_2007.pdf webcite
• [31]Gesundheitsberichterstattung des Bundes: Themenheft 31: HIV und AIDS. Robert Koch-Institut [cited on 17 November 2007]. Available from http://www.rki.de/cln_049/nn_199850/DE/Content/GBE/Gesundheitsberichterstattung/GBEDownloadsT/hiv__aids,templateId=raw,property=publicationFile.pdf/hiv_aids.pdf webcite
• [32]Gesundheit in Deutschland: Gesundheitsberichterstattung des Bundes. Robert Koch-Institut [cited on 17 September 2007]. Available from http://www.gbe-bund.de/gbe10/owards.prc_show _pdf?p_id=9965&p_sprache=D&p_uid=gast&p_aid=19790274&p_lfd_nr=1 webcite
• [33]Statistisches Bundesamt In Statistisches Jahrbuch für die Bundesrepublik Deutschland 2006. Wiesbaden: Statistisches Bundesamt; 2006.
• [34]EBM, Einheitlicher Bewertungsmaßstab, 4/2007 Kas-senärztliche Bundesvereinigung [cited on 26 September 2007]Available from http://www.kbv.de/ebm2000plus/EBMGesamt.htm webcite
• [35]DRG WebGrouper, 2007 DRG-Research-Group [cited on 1 July 2007]Available from http://drg.uni-muenster. de/de/webgroup/m.webgroup.php?menu=6 webcite
• [36]Übersicht über die für 2007 gültigen Landesbasisfallwerte in den einzelnen Bundesländern AOK-Bundesverband [cited on 8 June 2007]Available from http://www.aok-gesundheitspartner.de/imperia/md/content/gesundheitspartner/bund/krankenhaus/budgetverhandlungen/lbfw_2007_uebersicht.pdf webcite
• [37]Gebührenordnung für Ärzte (GOÄ): Gutermann Publisher Ltd [cited on 13 June 2008]. Available from http://www.e-bis.de/goae/defaultFrame.htm webcite
• [38]Lauer Taxe 2007 LAUER-FISCHER GmbH [cited on 23 September 2007]Available from http://www.lauer-fischer.de/LF/Seiten/Produkte/Online-Dienste/Lauer-Taxe%20online.aspx; webcite
• [39]Statistisches Bundesamt In Löhne und Gehälter Oktober 2006. Fachserie 16 Reihe 2.2. Wiesbaden: Statistisches Bundesamt; 2007.
• [40]Sozialversicherungspflichtig Beschäftigte nach Altersgruppen in der Bundesrepublik Deutschland Bundesagentur für Arbeit [cited on 13 June 2008]Available from http://www.pub.arbeitsamt.de/hst/services/statistik/aktuell/iiia6/sozbe/zr_svb_alterd.xls webcite
• [41]Daten zur kurzfristigen Entwicklung von Wirtschaft und Arbeitsmarkt. Ausgabe Nr. 12/2006 Institut für Arbeitsmarkt und Berufsforschung der Bundesagentur für Arbeit (IAB). [cited on 13 June 2008]Available from http://doku.iab.de/werkber/2006/wb_arbeitszeit.pdf webcite
• [42]The Division of AIDS Table for Grading the Severity of Adult and Pediatric Adverse Events, Version 1.0, Dec 2004 DAIDS (Division of Acquired Immunodeficiency Syndrome) [cited on 13 June 2008]Available from http://rcc.tech-res.com/eae.htm webcite